November 25, 2024 12:03 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Maharashtra Elections: Mahayuti's newly-elected MLAs to select CM in key meeting on Monday | Mahayuti routs MVA in Maharashtra, INDIA retains Jharkhand; Priyanka's triumphant poll debut | How can Mahayuti win over 200 seats? Sanjay Raut cries foul over Maharashtra mandate | 'Third World War has begun:' Ex-Ukraine military commander-in-chief Valery Zaluzhny | UK-India Free Trade Agreement negotiations to resume in early 2024
Applying for emergency use of Covid-19 vaccine in 2 weeks: Serum Institute
Covid-19 Vaccine
Image Credit: Narendra Modi Twitter Handle

Applying for emergency use of Covid-19 vaccine in 2 weeks: Serum Institute

| @indiablooms | 29 Nov 2020, 10:28 am

New Delhi/IBNS: The Serum Institute will apply within two weeks for an emergency license to use the coronavirus vaccine being developed by the University of Oxford and pharma giant AstraZeneca, the Indian vaccine maker's chief Adar Poonawalla said on Saturday after a meeting with Prime Minister Narendra Modi.

"As of now, we don't have anything in writing with the government of India on how many doses they will purchase but the indication is that it would be 300-400 million doses by July 2021," he told reporters at a press conference.

"We are in the process of applying in the next two weeks for the emergency use," he added.

PM Modi on Saturday visited Zydus Biotech Park in Ahmedabad and Bharat Biotech facility in Hyderabad to know more about the indigenous DNA based vaccine being developed by Zydus Cadila as well as the vaccine candidate by Bharat Biotech.

"At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous COVID-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress," PM Modi tweeted on Saturday. He later visited the Serum Institute in Pune too.

Poonawalla said, "At the moment the trials were more than enough for the efficacy. We might look at doing trials on group less than 18 years of age later on."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.